Study Title
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Purpose
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:
- Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)
- Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
For more information visit
https://clinicaltrials.gov/study/NCT05468489
Interested in Volunteering for the Study?
If you would like more information about this study, please call us at 318-212-8671.
Eligibility
Study Process
Trial Details
Investigator:
IRB:
** WK New Format
IRB Number:
Trial Type:
Device
Sponsor:
** WK New Format
Contact Information: